Ocuvex Therapeutics

What Ocuvex Therapeutics does

Ocuvex Therapeutics, Inc. is a privately held, US-incorporated specialty ophthalmic pharmaceutical company headquartered at One Bridge Plaza, 2nd Floor, Fort Lee, New Jersey. The company's commercial focus is the development and commercialization of branded topical ophthalmic therapies for ocular hypertension, open-angle glaucoma, and post-surgical inflammation and pain. Its commercial asset is OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002%, an FDA-approved (September 2022) selective EP2 receptor agonist indicated for reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Through the August 2024 merger with Visiox Pharmaceuticals, Ocuvex added PDP-716 and SDN-037 to its commercial portfolio.

The pipeline is built around two proprietary drug-delivery platforms: OVX-001 applies patented TearAct fine resin technology to deliver a once-daily glaucoma option, and OVX-002 uses the patented TJM micellar platform as a twice-daily topical corticosteroid for post-surgical inflammation and pain; Ocuvex retains global rights to both candidates. The commercial approach is sales-led, with a small named leadership team — Anthony Amato (President & CEO), David Friedman (President & COO; founder), and Michael Proctor (CCO, 43+ years experience) — and distribution executed through retail and specialty pharmacy channels targeting US ophthalmology prescribers and patients.

The business model is prescription pharmaceutical product sales with negotiation through insurance and pharmacy benefit managers; specific pricing is not publicly disclosed. On July 16, 2025, Ocuvex entered a definitive merger agreement with Nasdaq-listed Onconetix, Inc., under which Ocuvex equity holders would receive 90% of the combined public company (anticipated close Q4 2025), making this an active period of M&A-led portfolio expansion and a pending transition to public-company status. Revenue, headcount, funding history, and institutional investor data are not disclosed in available sources.

Name

Ocuvex Therapeutics

Legal name

Ocuvex Therapeutics, Inc.

Website

https://ocuvextherapeutics.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Ocuvex Therapeutics is a privately held US ophthalmic pharmaceutical company that develops and commercializes branded topical therapies for open-angle glaucoma, ocular hypertension, and post-surgical ocular inflammation, anchored by the FDA-approved product OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002% and a pipeline built on TearAct and TJM micellar delivery platforms.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Rare Ophthalmology Disorder Therapies (HLAIAIAK)

Keywords

• Ophthalmic pharmaceuticals
• Glaucoma treatments
• Ocular drug delivery
• Prescription eye drops
• Ophthalmic therapeutics

Headquarters

HQ city

Fort Lee

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the sale of prescription ophthalmic pharmaceutical products including OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002%, approved by the FDA in September 2022 for reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Ocuvex Therapeutics is a privately held ophthalmic pharmaceutical company that develops, acquires, and commercializes prescription therapeutics for ocular diseases. Its flagship approved product is OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002%, an FDA-approved EP2 receptor agonist for reducing elevated intraocular pressure in open-angle glaucoma and ocular hypertension. The pipeline includes OVX-001 (once-daily glaucoma drops using TearAct resin technology) and OVX-002 (twice-daily topical corticosteroid using the TJM micellar platform) for post-surgical inflammation and pain, along with acquired assets PDP-716 and SDN-037 from the Visiox merger.

Product overview

Ocuvex Therapeutics is a pharmaceutical company focused on ophthalmology with a portfolio of approved and pipeline products. The core product is OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002%, an FDA-approved prescription eye drop for glaucoma and ocular hypertension. The pipeline includes OVX-001 (once-daily glaucoma treatment using TearAct fine resin technology) and OVX-002 (twice-daily corticosteroid for post-surgical inflammation using TJM micellar platform). Through the August 2024 merger with Visiox Pharmaceuticals, the company acquired additional products including PDP-716 and SDN-037. The combined entity operates under the Ocuvex name, focusing on glaucoma and post-surgical inflammation and pain therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• Omlonti: Prescription eye drop for treatment of glaucoma and ocular hypertension. Omidenepag isopropyl ophthalmic solution 0.002%, a prodrug of omidenepag, a relatively selective EP2 receptor agonist for reducing elevated intraocular pressure.
• OVX-001
• OVX-002

Products and services

• OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002% Prescription eye drop for reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension; prodrug of omidenepag acting as a relatively selective EP2 receptor agonist with a dual mechanism of action.
• OVX-001 Once-daily ophthalmic drops for ocular hypertension and open-angle glaucoma utilizing patented TearAct fine resin technology for enhanced drug delivery.
• OVX-002 Twice-daily topical corticosteroid option for post-surgical inflammation and pain utilizing patented TJM micellar platform technology for effective corticosteroid delivery.
• PDP-716 Ophthalmic product acquired via the Visiox Pharmaceuticals merger, included in the combined entity's enhanced ophthalmic market presence.
• SDN-037 Ophthalmic product acquired via the Visiox Pharmaceuticals merger, included in the combined entity's enhanced ophthalmic market presence.

Quantifiable outcome

• FDA approval of OMLONTI® in September 2022 for reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension patients

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• OnconetixcoreStrategic or Co-development Partner · 16 July 2025Onconetix (Nasdaq: ONCO) entered into a definitive merger agreement with Ocuvex Therapeutics in July 2025. Upon closing, Ocuvex equity holders will receive 90% of the combined company on a fully diluted basis, with Onconetix shareholders retaining 10%. The transaction aims to provide Ocuvex access to public capital markets and accelerate development of ophthalmic treatments. Completion anticipated in Q4 2025.
• Visiox PharmaceuticalscoreStrategic or Co-development Partner · 19 August 2024Visiox Pharmaceuticals merged with Ocuvex Therapeutics in August 2024 to strengthen the ophthalmic portfolio and accelerate product commercialization. The combined entity operates under the Ocuvex name, enhancing market presence with products including OMLONTI, PDP-716, and SDN-037.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Ocular Therapeutix: Specialty ophthalmic pharmaceutical company that develops and commercializes proprietary drug-delivery formulations for eye diseases, using sustained-release hydrogel technology. Highly comparable given its similar model of combining a commercial ophthalmic asset (DEXTENZA) with a pipeline built around a novel delivery platform.
• Harrow Health: US-based specialty ophthalmic pharmaceutical company commercializing branded ocular drugs (IHEEZO, VEVYE, FLAREX, etc.), with a model built on acquiring and relaunching underutilized ophthalmic assets. Directly comparable in commercial-stage specialty ophthalmics, asset acquisition strategy, and target prescribers.
• Nicox: European specialty ophthalmic company focused on glaucoma therapeutics (latanoprostene bunod / VYZULTA) and ocular surface diseases. Comparable for its specialty-pharma focus on glaucoma, smaller commercial scale, and pipeline expansion via in-licensing.
• Eyenovia: Ophthalmic biotech developing therapeutics delivered via its proprietary Optejet dispenser platform, including treatments for mydriasis, myopia progression and presbyopia. Comparable for its emphasis on a patented drug-delivery platform for topical eye therapies.

Broad incumbents

• Alcon: Global leader in ophthalmic pharmaceuticals, surgical devices and vision care with a deep glaucoma franchise (including the Aerie acquisition). Broad incumbent competitor across the same therapeutic areas Ocuvex is targeting.
• Bausch + Lomb: Major diversified ophthalmic company with branded prescription eye drops (including glaucoma and post-surgical inflammation therapies). Anchors reference for what an at-scale incumbent commercial footprint looks like in Ocuvex's target categories.
• AbbVie (Allergan Aesthetics / Eye Care): Inheritor of Allergan's leading ophthalmic franchise including LUMIGAN and other prostaglandin-class glaucoma drugs. Largest competitive presence in OMLONTI's category and a benchmark for intraocular-pressure market share.
• Santen Pharmaceutical: Japan-headquartered global specialty ophthalmic pharma with a major glaucoma franchise (TAPTIQOM, DE-117/RYZUMVI). Comparable for its specialty-ophthalmic focus and pipeline depth in glaucoma and ocular surface.

Emerging players

• Tarsus Pharmaceuticals: US specialty eye-care pharma commercializing XDEMVY for Demodex blepharitis, demonstrating what a focused ophthalmic pharma commercial launch looks like. Useful emerging-stage comparator for go-to-market approach and prescriber relationships.

Others

• ImprimisRx (Harrow subsidiary / specialty ophthalmic channel): Specialty pharmacy platform distributing compounded ophthalmic formulations; relevant ecosystem comparator for the distribution-side approach to specialty ophthalmic prescribing and patient access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ocuvex

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ocuvex Therapeutics